Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB078 multiple-ascending-dose intrathecal study in adults with C9ORF72-associated ALS
NL-OMON55647Phase 1Active, not recruiting
- Sponsor
- Biogen
- Start
- Jul 2019
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial in amyotrophic lateral sclerosis (ALS) comparing BIIB078 with Placebo (2 arms). Primary endpoint: Adverse events and serious adverse events. Started Jul 2019; status: active, not recruiting.
02
Drugs
tadnersen
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON55647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55647.